Biomedical Engineering Reference
In-Depth Information
67. Sudhakaran S, Ghabrial H, Nation RL, Kong DC, Gude NM, Angus PW, Rayner CR. 2005.
Differential bidirectional transfer of indinavir in the isolated perfused human placenta.
Antimicrob Agents Chemother 49: 1023-1028.
68. Molsa M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, Wadelius M, Wadelius C,
Laine K. 2005. Functional role of P-glycoprotein in the human blood-placental barrier.
Clin Pharmacol Ther 78: 123-131.
69. Wacher VJ, Wu CY, Benet LZ. 1995. Overlapping substrate specificities and tissue dis-
tribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and
activity in cancer chemotherapy. Mol Carcinog 13: 129-134.
70. Watkins PB. 1997. The barrier function of CYP3A4 and P-glycoprotein in the small
bowel. Adv Drug Deliv Rev 27: 161-170.
71. Bigger JT, Leahey EB. 1982. Quinidine and digoxin. An important interaction. Drugs 24:
229-239.
72. Leahey EB, Reiffel JA, Heissenbuttel RH, Drusin RE, Lovejoy WP, Bigger JT Jr. 1979.
Enhanced cardiac effect of digoxin during quinidine treatment. Arch Intern Med 139:
519-521. Abstract only.
73. Doering W. 1979. Quinidine-digoxin interaction: pharmacokinetics, underlying mecha-
nism and clinical implications. N Engl J Med 301: 400-404.
74. Klein HO, Lang R, Weiss E, Di Segni E, Libhaber C, Guerrero J, Kaplinsky E. 1982. The
influence of verapamil on serum digoxin concentration. Circulation 65: 998-1003.
75. Belz GG, Doering W, Munkes R, Matthews J. 1983. Interaction between digoxin and
calcium antagonists and antiarrhythmic drugs. Clin Pharmacol Ther 33: 410-417.
76. Calvo MV, Martin-Suarez A, Martin Luengo C, Avila C, Cascon M, Dominguez-Gil Hurle
A. 1989. Interaction between digoxin and propafenone. Ther Drug Monit 11: 10-15.
77. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R,
Terhaag B, Kroemer HK, Siegmund W. 2000. Oral bioavailability of digoxin is enhanced
by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther
68: 6-12.
78. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, Inui KI. 1998.
Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein.
Clin Pharmacol Ther 64: 123-128.
79. Jalava KM, Partanen J, Neuvonen PJ. 1997. Itraconazole decreases renal clearance of
digoxin. Ther Drug Monit 19: 609-613.
80. Maxwell DL, Gilmour-White SK, Hall MR. 1989. Digoxin toxicity due to interaction of
digoxin with erythromycin. BMJ 298: 572.
81. Hinderling PH, Hartmann D. 1991. Pharmacokinetics of digoxin and main metabo-
lites/derivatives in healthy humans. Ther Drug Monit 13: 381-401.
82. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. 1999. Inhibition of P-
glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction
between digoxin and quinidine. Circulation 99: 552-557.
83. Hori R, Okamura N, Aiba T, Tanigawara Y. 1993. Role of P-glycoprotein in renal tubular
secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 266:
1620-1625.
84. De Lannoy IA, Koren G, Klein J, Charuk J, Silverman M. 1992. Cyclosporin and quinidine
inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am J
Physiol 263: F613-F622.
Search WWH ::
Custom Search